Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Regorafenib
Related studies linked through entity extraction aliases.
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
- Status
- COMPLETED
- Phase
- PHASE2
Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Regorafenib and Cetuximab in Patients With Advanced Malignancy
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
- Status
- COMPLETED
- Phase
- PHASE2
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
- Status
- COMPLETED
- Phase
- PHASE2
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer
- Status
- COMPLETED
- Phase
- NA
Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers
- Status
- UNKNOWN
- Phase
- PHASE2
Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)
- Status
- COMPLETED
- Phase
- PHASE2
FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma
- Status
- COMPLETED
- Phase
- PHASE2
Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
- Status
- COMPLETED
- Phase
- PHASE2